withanolides has been researched along with Chemical-and-Drug-Induced-Liver-Injury* in 6 studies
6 other study(ies) available for withanolides and Chemical-and-Drug-Induced-Liver-Injury
Article | Year |
---|---|
Assessment of hepatoprotective and nephroprotective potential of withaferin A on bromobenzene-induced injury in Swiss albino mice: possible involvement of mitochondrial dysfunction and inflammation.
Bromobenzene is a well-known environmental toxin which causes liver and kidney damage through CYP450-mediated bio-activation to generate reactive metabolites and, consequently, oxidative stress. The present study aimed to evaluate the possible protective role of withaferin A against bromobenzene-induced liver and kidney damage in mice. Withaferin A (10 mg/kg) was administered orally to the mice for 8 days before intragastric intubation of bromobenzene (10 mmol/kg). As results of this experiment, the levels of liver and kidney functional markers, lipid peroxidation, and cytokines (TNF-α and IL-1β) presented an increase and there was a decrease in anti-oxidant activity in the bromobenzene-treated group of mice. Pre-treatment with withaferin A not only significantly decreased the levels of liver and kidney functional markers and cytokines but also reduced oxidative stress, as evidenced by improved anti-oxidant status. In addition, the mitochondrial dysfunction shown through the decrease in the activities of mitochondrial enzymes and imbalance in the Bax/Bcl-2 expression in the livers and kidneys of bromobenzene-treated mice was effectively prevented by pre-administration of withaferin A. These results validated our conviction that bromobenzene caused liver and kidney damage via mitochondrial pathway and withaferin A provided significant protection against it. Thus, withaferin A may have possible usage in clinical liver and kidney diseases in which oxidative stress and mitochondrial dysfunction may be existent. Topics: Animals; Antioxidants; Bromobenzenes; Chemical and Drug Induced Liver Injury; Female; Inflammation; Interleukin-1beta; Kidney; Kidney Diseases; Lipid Peroxidation; Liver; Male; Mice; Mitochondria; Oxidants; Oxidative Stress; Random Allocation; Tumor Necrosis Factor-alpha; Withanolides | 2016 |
Withaferin A induces Nrf2-dependent protection against liver injury: Role of Keap1-independent mechanisms.
Small molecules of plant origin offer presumptively safe opportunities to prevent carcinogenesis, mutagenesis and other forms of toxicity in humans. However, the mechanisms of action of such plant-based agents remain largely unknown. In recent years the stress responsive transcription factor Nrf2 has been validated as a target for disease chemoprevention. Withania somnifera (WS) is a herb used in Ayurveda (an ancient form of medicine in South Asia). In the recent past, withanolides isolated from WS, such as Withaferin A (WA) have been demonstrated to be preventive and therapeutic against multiple diseases in experimental models. The goals of this study are to evaluate withanolides such as WA as well as Withania somnifera root extract as inducers of Nrf2 signaling, to probe the underlying signaling mechanism of WA and to determine whether prevention of acetaminophen (APAP)-induced hepatic toxicity in mice by WA occurs in an Nrf2-dependent manner. We observed that WA profoundly protects wild-type mice but not Nrf2-disrupted mice against APAP hepatotoxicity. WA is a potent inducer of Nrf2-dependent cytoprotective enzyme expression both in vivo and in vitro. Unexpectedly, WA induces Nrf2 signaling at least in part, in a Keap1-independent, Pten/Pi3k/Akt-dependent manner in comparison to prototypical Nrf2 inducers, sulforaphane and CDDO-Im. The identification of WA as an Nrf2 inducer that can signal through a non-canonical, Keap1-independent pathway provides an opportunity to evaluate the role of other regulatory partners of Nrf2 in the dietary and pharmacological induction of Nrf2-mediated cytoprotection. Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Cytotoxins; Fibroblasts; Gene Expression Regulation; Kelch-Like ECH-Associated Protein 1; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-E2-Related Factor 2; Phosphatidylinositol 3-Kinases; Plant Roots; Primary Cell Culture; Protective Agents; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Withania; Withanolides | 2016 |
Withaferin-A Reduces Acetaminophen-Induced Liver Injury in Mice.
Withaferin-A (WA) has anti-oxidant activities however, its therapeutic potential in acetaminophen (APAP) hepatotoxicity is unknown. We performed a proof-of-concept study to assess the therapeutic potential of WA in a mouse model that mimics APAP-induced liver injury (AILI) in humans. Overnight fasted C57BL/6NTac (5-6 wk. old) male mice received 200 mg/kg APAP intraperitoneally (i.p.). After 1 h mice were treated with 40 mg/kg WA or vehicle i.p., and euthanized 4 and 16 h later; their livers were harvested and serum collected for analysis. At 4 h, compared to vehicle-treated mice, WA-treated mice had reduced serum ALT levels, hepatocyte necrosis and intrahepatic hemorrhage. All APAP-treated mice had reduced hepatic glutathione (GSH) levels however, reduction in GSH was lower in WA-treated when compared to vehicle-treated mice. Compared to vehicle-treated mice, livers from WA-treated mice had reduced APAP-induced JNK activation, mitochondrial Bax translocation, and nitrotyrosine generation. Compared to vehicle-treated mice, WA-treated mice had increased hepatic up-regulation of Nrf2, Gclc and Nqo1, and down-regulation of Il-6 and Il-1β. The hepatoprotective effect of WA persisted at 16 h. Compared to vehicle-treated mice, WA-treated mice had reduced hepatocyte necrosis and hepatic expression of Il-6, Tnf-α and Il-1β, increased hepatic Gclc and Nqo1 expression and GSH levels, and reduced lipid peroxidation. Finally, in AML12 hepatocytes, WA reduced H₂O₂-induced oxidative stress and necrosis by preventing GSH depletion. Collectively, these data show mechanisms whereby WA reduces necrotic hepatocyte injury, and demonstrate that WA has therapeutic potential in AILI. Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antioxidants; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Crosses, Genetic; Glutathione; Hemorrhage; Inflammation Mediators; Injections, Intraperitoneal; Lipid Peroxidation; Liver; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Necrosis; Oxidative Stress; Random Allocation; Specific Pathogen-Free Organisms; Withanolides | 2015 |
Golden berry juice attenuates the severity of hepatorenal injury.
The aim of the present work is to investigate the potential of Physalis peruviana fruits as a hepatorenal protective agent against carbon tetrachloride (CCl4)-induced hepatic and renal fibrosis. The phytochemical screening test revealed the presence of alkaloids, free withanolides, glycowithanolides, and flavonoids. Acute toxicity study (500, 1000, and 1500 mg/kg body weight) revealed extract safety. The biological evaluation was conducted on different animal groups: control, control treated with fruit, CCl4 group, CCl4 treated with fruit, and CCl4 treated with silymarin drug. The evaluation was done through measuring oxidative stress markers: malondialdehyde (MDA), superoxide dismutase (SOD), and nitric oxide (NO). Liver function indices such as aspartate and alanine aminotransferases (AST & ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), bilirubin, and total protein were estimated. Kidney disorder biomarkers such as creatinine, urea, and serum protein were also evaluated. Treatment improved all the investigated parameters, and the histopathological analysis confirmed our results. In conclusion, Physalis peruviana fruit succeeded to protect liver and kidney against fibrosis. Further studies are needed to identify the molecules responsible for its pharmacological application. Topics: Alkaloids; Animals; Antioxidants; Beverages; Bilirubin; Biomarkers; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Fibrosis; Flavonoids; Fruit; Kidney; Kidney Diseases; Lipid Peroxidation; Liver; Male; Malondialdehyde; Oxidative Stress; Physalis; Phytotherapy; Plant Preparations; Rats; Rats, Wistar; Severity of Illness Index; Withanolides | 2013 |
Effect of Withania somnifera glycowithanolides on iron-induced hepatotoxicity in rats.
Glycowithanolides, consisting of equimolar concentrations of sitoindosides VII-X and withaferin A, isolated from the roots of Withania somnifera Dunal, have been reported to have an antioxidant effect in the rat brain frontal cortex and striatum. In the present study, the effect of 10 days of oral administration of these active principles, in graded doses (10, 20 and 50 mg/kg), was noted on iron overload (FeSo(4), 30 mg/kg, i.p.) induced hepatotoxicity in rats. Apart from hepatic lipid peroxidation (LPO), the serum enzymes, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase, were assessed as indices of hepatotoxicity. Silymarin (20 mg/kg, p.o.) was used for comparison. Iron overload induced marked increase in hepatic LPO and serum levels of the enzymes, which was attenuated by WSG in a dose-related manner, and by silymarin. The results indicate that the reported use of WS in Ayurveda for hepatoprotection against heavy metals and other environmental toxins, may be due the antioxidant action of WSG. Topics: Administration, Oral; Animals; Chemical and Drug Induced Liver Injury; Ergosterol; Ferrous Compounds; Hepatocytes; Lipid Peroxidation; Male; Phytotherapy; Plant Extracts; Protective Agents; Rats; Rats, Inbred Strains; Sitosterols; Solanaceae; Withanolides | 2000 |
Comparison of the protective effect of Withaferin-'A' and hydrocortisone against CCL4 induced hepatotoxicity in rats.
Protective effect of Withaferin-'A' against CCl4 induced hepatotoxicity has been assessed and the compound at 10 mg/kg dose was found to possess significant protective effect. A comparison of this protective effect with that of hydrocortisone showed it to be as effective as hydrocortisone dose per dose. Topics: Alkaline Phosphatase; Animals; Blood Proteins; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Drug Interactions; Ergosterol; Female; Hydrocortisone; Liver; Liver Diseases; Male; Rats; Withanolides | 1992 |